Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.92
HZNP's Cash to Debt is ranked lower than
63% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.38 vs. HZNP: 0.92 )
HZNP' s 10-Year Cash to Debt Range
Min: 0.07   Max: N/A
Current: 0.92

Equity to Asset 0.45
HZNP's Equity to Asset is ranked lower than
76% of the 546 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. HZNP: 0.45 )
HZNP' s 10-Year Equity to Asset Range
Min: -0.77   Max: 0.7
Current: 0.45

-0.77
0.7
F-Score: 4
Z-Score: 3.35
M-Score: -0.33
WACC vs ROIC
17.51%
8.27%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -1.48
HZNP's Operating margin (%) is ranked lower than
75% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.91 vs. HZNP: -1.48 )
HZNP' s 10-Year Operating margin (%) Range
Min: -1841.5   Max: -2.86
Current: -1.48

-1841.5
-2.86
Net-margin (%) -21.47
HZNP's Net-margin (%) is ranked lower than
84% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.82 vs. HZNP: -21.47 )
HZNP' s 10-Year Net-margin (%) Range
Min: -1635.12   Max: -88.77
Current: -21.47

-1635.12
-88.77
ROE (%) -24.57
HZNP's ROE (%) is ranked lower than
82% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.24 vs. HZNP: -24.57 )
HZNP' s 10-Year ROE (%) Range
Min: -523.78   Max: -57.66
Current: -24.57

-523.78
-57.66
ROA (%) -8.71
HZNP's ROA (%) is ranked lower than
77% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.16 vs. HZNP: -8.71 )
HZNP' s 10-Year ROA (%) Range
Min: -176.97   Max: -31.86
Current: -8.71

-176.97
-31.86
ROC (Joel Greenblatt) (%) -56.66
HZNP's ROC (Joel Greenblatt) (%) is ranked lower than
81% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.15 vs. HZNP: -56.66 )
HZNP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5030.52   Max: -154.09
Current: -56.66

-5030.52
-154.09
Revenue Growth (3Y)(%) 66.40
HZNP's Revenue Growth (3Y)(%) is ranked higher than
97% of the 537 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. HZNP: 66.40 )
HZNP' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 66.4
Current: 66.4

0
66.4
EPS Growth (3Y)(%) -36.90
HZNP's EPS Growth (3Y)(%) is ranked lower than
87% of the 439 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.40 vs. HZNP: -36.90 )
HZNP' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: -36.9
Current: -36.9

» HZNP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

HZNP Guru Trades in Q2 2014

Joel Greenblatt 57,769 sh (New)
Paul Tudor Jones Sold Out
» More
Q3 2014

HZNP Guru Trades in Q3 2014

Paul Tudor Jones 294,814 sh (New)
Steven Cohen 934,396 sh (New)
Joel Greenblatt 80,834 sh (+39.93%)
» More
Q4 2014

HZNP Guru Trades in Q4 2014

Steven Cohen 2,614,700 sh (+179.83%)
Joel Greenblatt 107,898 sh (+33.48%)
Paul Tudor Jones 274,577 sh (-6.86%)
» More
Q1 2015

HZNP Guru Trades in Q1 2015

Jim Simons 359,430 sh (New)
Joel Greenblatt Sold Out
Paul Tudor Jones 45,508 sh (-83.43%)
Steven Cohen 233,900 sh (-91.05%)
» More
» Details

Insider Trades

Latest Guru Trades with HZNP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 11.78
HZNP's Forward P/E is ranked higher than
85% of the 266 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.66 vs. HZNP: 11.78 )
N/A
P/B 6.00
HZNP's P/B is ranked lower than
88% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. HZNP: 6.00 )
HZNP' s 10-Year P/B Range
Min: 0.8   Max: 14.89
Current: 6

0.8
14.89
P/S 8.90
HZNP's P/S is ranked lower than
100% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. HZNP: 8.90 )
HZNP' s 10-Year P/S Range
Min: 1.47   Max: 19.46
Current: 8.9

1.47
19.46
EV-to-EBIT -940.40
HZNP's EV-to-EBIT is ranked lower than
177% of the 472 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.75 vs. HZNP: -940.40 )
HZNP' s 10-Year EV-to-EBIT Range
Min: -766.4   Max: -0.1
Current: -940.4

-766.4
-0.1
Current Ratio 3.75
HZNP's Current Ratio is ranked higher than
68% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.37 vs. HZNP: 3.75 )
HZNP' s 10-Year Current Ratio Range
Min: 0.16   Max: 4.39
Current: 3.75

0.16
4.39
Quick Ratio 3.68
HZNP's Quick Ratio is ranked higher than
72% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.72 vs. HZNP: 3.68 )
HZNP' s 10-Year Quick Ratio Range
Min: 0.16   Max: 4.27
Current: 3.68

0.16
4.27
Days Inventory 53.25
HZNP's Days Inventory is ranked higher than
81% of the 609 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.49 vs. HZNP: 53.25 )
HZNP' s 10-Year Days Inventory Range
Min: 13.1   Max: 184.95
Current: 53.25

13.1
184.95
Days Sales Outstanding 129.69
HZNP's Days Sales Outstanding is ranked lower than
81% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.43 vs. HZNP: 129.69 )
HZNP' s 10-Year Days Sales Outstanding Range
Min: 67.08   Max: 124.99
Current: 129.69

67.08
124.99

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 36.30
HZNP's Price/DCF (Projected) is ranked lower than
137% of the 326 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. HZNP: 36.30 )
HZNP' s 10-Year Price/DCF (Projected) Range
Min: 14.99   Max: 409.33
Current: 36.3

14.99
409.33
Price/Median PS Value 1.90
HZNP's Price/Median PS Value is ranked lower than
85% of the 615 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. HZNP: 1.90 )
HZNP' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 3.77
Current: 1.9

0.38
3.77
Earnings Yield (Greenblatt) -0.10
HZNP's Earnings Yield (Greenblatt) is ranked lower than
76% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.60 vs. HZNP: -0.10 )
HZNP' s 10-Year Earnings Yield (Greenblatt) Range
Min: -1.1   Max: 0
Current: -0.1

-1.1
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:HPR.Germany,
Horizon Pharma PLC was incorporated on March 23, 2010. The Company is a specialty pharmaceutical company commercializing DUEXIS, VIMOVO and RAYOS/LODOTRA, each of which targets unmet therapeutic needs in arthritis, pain and inflammatory diseases. DUEXIS is a proprietary single tablet formulation containing a fixed-dose combination of ibuprofen, one of the widely prescribed NSAIDs, and famotidine, a well-established GI agent used to treat dyspepsia, gastroesophageal reflux disease, or GERD, and active ulcers, in one pill. Ibuprofen has proven anti-inflammatory and analgesic properties and famotidine reduces the stomach acid secretion that can cause upper GI ulcers. VIMOVO is a proprietary fixed-dose multi-layer delayed-release tablet combining an enteric-coated naproxen, an NSAID, core and an immediate-release esomeprazole, a PPI, layer surrounding the core. Naproxen has proven anti-inflammatory and analgesic properties and esomeprazole reduces the stomach acid secretions that can cause upper GI ulcers. RAYOS, known as LODOTRA outside the United States, is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults particularly when accompanied by morning stiffness. DUEXIS and VIMOVO compete with other branded NSAIDs, including Celebrex, marketed by Pfizer Inc. RAYOS/LODOTRA competes in Europe and in the United States with a number of products on the market to treat RA, including corticosteroids, such as prednisone, traditional DMARDs, such as methotrexate and biologic agents, such as HUMIRA and Enbrel.
» More Articles for HZNP

Headlines

Articles On GuruFocus.com
hznp May 24 2015 
M&A’s Driving The Stock Indexes Ahead Apr 06 2015 
Biotech Effectiveness: Horizon Pharma, Zafgen, XOMA Corp Mar 09 2015 
Horizon Pharma plc to Host Fourth Quarter 2014 Conference Call and Webcast on February 27, 2015 Jan 28 2015 
Horizon Pharma plc Provides Business Update Jan 12 2015 
Horizon Pharma plc Files Patent Infringement Lawsuit Against Watson Laboratories, Inc. for Filing an Dec 24 2014 
Horizon Pharma plc to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 24 2014 
Horizon Pharma plc Announces Pricing of Secondary Offering of Ordinary Shares by Selling Shareholder Nov 14 2014 
Horizon Pharma plc Announces Proposed Secondary Offering of Ordinary Shares by Selling Shareholders Nov 13 2014 
Horizon Pharma plc Announces Favorable Markman Ruling in RAYOS(R) (prednisone) Delayed-Release Table Nov 12 2014 

More From Other Websites
Growth stocks demand action from momentum players May 26 2015
Notable option activity in equities May 26 2015
VIDEO: 10 Growth Stocks in 10 Minutes May 23 2015
Horizon Pharma Up On Bullish Leerink Initiation May 22 2015
Coverage initiated on Horizon Pharma by Leerink Partners May 22 2015
Horizon Pharma plc to Participate in Two Conferences in June May 21 2015
Horizon Pharma plc to Participate in Two Conferences in June May 21 2015
Horizon Pharmaceuticals (HZNP) Stock is Today's 'Chart of the Day' May 18 2015
HORIZON PHARMA PLC Financials May 16 2015
Horizon Pharma plc Announces That Amy Grahn Honored as a 2015 Healthcare Businesswomen's Association... May 14 2015
Horizon Pharma plc Announces That Amy Grahn Honored as a 2015 Healthcare Businesswomen's Association... May 14 2015
10-Q for Horizon Pharma, Inc. May 11 2015
HORIZON PHARMA PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of... May 11 2015
Horizon Pharma Net Rises 62%, Sales Double, Guidance Lifted May 08 2015
Horizon Pharma (HZNP) Stock Tanks on Mixed Earnings May 08 2015
Horizon Pharma Q1 Mixed, Settles Suit With Perrigo May 08 2015
Horizon Pharma reports 1Q loss, misses expectations May 08 2015
Horizon Pharma reports 1Q loss, misses expectations May 08 2015
Horizon Pharma (HZNP) Misses Earnings, Upped View - Tale of the Tape May 08 2015
Horizon Pharma plc Announces First Quarter 2015 Financial Results and Increases 2015 Guidance May 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK